Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions
Authors:
- Sara E. SchadSSSara E. Schad
- Andrew ChowACAndrew Chow
- Levi MangarinLMLevi Mangarin
- Heng PanHPHeng Pan
- Jiajia ZhangJZJiajia Zhang
- Nicholas CegliaNCNicholas Ceglia
- Justina X. CaushiJCJustina X. Caushi
- Nicole MalandroNMNicole Malandro
- Roberta ZappasodiRZRoberta Zappasodi
- Mathieu GigouxMGMathieu Gigoux
- Daniel HirschhornDHDaniel Hirschhorn
- Sadna BudhuSBSadna Budhu
Open Access
- 23 May 2022
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (6)
Abstract
Transcription factors ThPOK and Runx3 regulate the differentiation of “helper” CD4+ and “cytotoxic” CD8+ T cell lineages respectively, inducing single positive (SP) T cells that enter the periphery with the expression of either the CD4 or CD8 co-receptor. Despite the expectation that these cell fates are mutually exclusive and that mature CD4+CD8+ double positive (DP) T cells are present in healthy individuals and augmented in the context of disease, yet their molecular features and pathophysiologic role are disputed. Here, we show DP T cells in murine and human tumors as a heterogenous population originating from SP T cells which re-express the opposite co-receptor and acquire features of the opposite cell type’s phenotype and function following TCR stimulation. We identified distinct clonally expanded DP T cells in human melanoma and lung cancer by scRNA sequencing and demonstrated their tumor reactivity in cytotoxicity assays. Our findings indicate that antigen stimulation induces SP T cells to differentiate into DP T cell subsets gaining in polyfunctional characteristics.Keywords
Funding Information
- National Institutes of Health (P30 CA008748)
- National Cancer Institute (NCI R01 CA056821)
- Swim Across America
- Ludwig Institute for Cancer Research
- Memorial Sloan Kettering
- Cancer Research Institute
- Parker Institute for Cancer Immunotherapy
- Cancer Immunology Translational Cancer Research (SU2C-AACR-DT1012)
- Cancer Research Institute-Stand Up 2 Cancer
- John Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy
- Bristol-Myers Squibb International Immuno-Oncology Network
- National Cancer Institute (P30 CA08748)
- Cycle for Survival
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
This publication has 43 references indexed in Scilit:
- Combining Next-Generation Sequencing and Immune Assays: A Novel Method for Identification of Antigen-Specific T CellsPLOS ONE, 2013
- CD4+CD8+ T Cells Represent a Significant Portion of the Anti-HIV T Cell Response to Acute HIV InfectionThe Journal of Immunology, 2012
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaJournal of Experimental Medicine, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- CD8+ T cell concentration determines their efficiency in killing cognate antigen–expressing syngeneic mammalian cells in vitro and in mouse tissuesJournal of Experimental Medicine, 2010
- Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLsJournal of Experimental Medicine, 2009
- The Zinc Finger Transcription Factor Zbtb7b Represses CD8-Lineage Gene Expression in Peripheral CD4+ T CellsImmunity, 2008
- ThPOK acts late in specification of the helper T cell lineage and suppresses Runx-mediated commitment to the cytotoxic T cell lineageNature Immunology, 2008
- Tumor-specific Th17-polarized cells eradicate large established melanomaBlood, 2008
- Peripheral CD4+CD8+ T cells are differentiated effector memory cells with antiviral functionsBlood, 2004